Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Diarrhea 1

Interventions

Carboplatin 330Pemetrexed 266Cisplatin 234Docetaxel 195Paclitaxel 182Radiotherapy 178Erlotinib Hydrochloride 153Gemcitabine 147pembrolizumab 146Bevacizumab 125Drug Therapy 121Radiosurgery 114Nivolumab 112osimertinib 92durvalumab 88Gefitinib 67atezolizumab 63Vinorelbine 63Surgical Procedures, Operative 62Magnetic Resonance Spectroscopy 53anlotinib 42Immunotherapy 42Taxes 39Blood Specimen Collection 39Ipilimumab 38130-nm albumin-bound paclitaxel 38Specimen Handling 36Immune Checkpoint Inhibitors 35Radiation 33Albumin-Bound Paclitaxel 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Non-Small-Cell Lung × Theophylline × Clear all
NCT02080078 2019-05-03

A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline

AHS Cancer Control Alberta

Phase 1 Terminated
15 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Diarrhea

NCT01799161 2014-11-17

Combination of gp96-Ig Vaccine, Theophylline and Oxygen for the Treatment of Patients With Advanced, Relapsed or Metastatic Non-Small Cell Lung Cancer

University of Miami

Phase 1 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡